Black Diamond Therapeutics (BDTX) Stock: Buy, Sell, or Hold?
BDTX - Black Diamond Therapeutics, Inc. Common Stock
$2.08
0.00 (0.00%)
▲
5d:
+19.54%
30d:
+9.47%
90d:
+18.18%
WAIT
LOW Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Nov 05, 2026
13d
Get Alerted When BDTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: BDTX shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: BDTX shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: BDTX is currently trading at $2.08, which is considered extended relative to its 30-day fair value range of $1.78 to $1.98.
Technical Outlook: Technically, BDTX is in a uptrend. The price is approaching resistance at $2.14. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: BDTX scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $10.00 (+380.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BDTX is in a uptrend. The price is approaching resistance at $2.14. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: BDTX scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $10.00 (+380.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.78 -
$1.98
Company Quality Score
38/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
21.1%
All Signals
- BEARISH: Price extended above range (+5.1% above its trading range)
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 380.8% below Wall St target ($10.00)
- WARNING: Composite score 38/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.78 -
$1.98
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.60
Resistance Level
$2.14
Current Trend
Uptrend
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.08
Wall Street Target
$10.00
(+380.8%)
Share & Embed Analysis
Last updated: October 22, 2026 5:44 PM ET
Data refreshes hourly during market hours. Next update: 6:44 PM
Data refreshes hourly during market hours. Next update: 6:44 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BDTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
24 analysts |
$139 | 58 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
25 analysts |
$1153 | 52 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
23 analysts |
$108 | 58 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
22 analysts |
$283 | 49 HOLD |
|
IRD
Opus Genetics, Inc. |
STRONG BUY
18 analysts |
$13 | 58 HOLD |
